Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3329436 | Critical Reviews in Oncology/Hematology | 2009 | 7 Pages |
Abstract
Inflammatory cells produce a proliferation inducing ligand (APRIL), one of the most recently cloned members of the tumor necrosis factor (TNF) family. Early experiments implicated APRIL as a promoting factor in the natural course of various cancers, reinforcing the concept that host inflammatory reactions are part of a tumor development. Recent studies have further analyzed the tumor-promoting role of APRIL in patients with solid tumors or with hematological malignancies. Here, we will review the recent literature, and provide evidence that APRIL may be a useful prognostic tool and a potential target in the treatment of some cancers.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
E. Roosnek, M. Burjanadze, P.Y. Dietrich, T. Matthes, J. Passweg, B. Huard,